Teleflex Introduces the ArrowADVANTAGE5 ™ Pressure-Injectable PICC

LIMERICK, Pa.--(BUSINESS WIRE)--

Teleflex Incorporated TFX today announced the launch of the ArrowADVANTAGE⁵ pressure-injectable peripherally inserted central catheter (PICC). ArrowADVANTAGE⁵ provides features clinicians have come to expect in a PICC, plus five unique advantages. The design was developed for clinician ease-of-use, smooth insertion and patient comfort.

“With the ArrowADVANTAGE⁵ PICC, we have introduced our next generation of non-coated pressure-injectable PICC. Beyond the unique advantages of our PICC, the distal lumen is also VasoNova^® VPS^™ compatible¹, allowing clinicians to combine the advantages of our PICC with state-of-the art tip location technology,” commented Paul Molloy, President, Vascular Division of Teleflex.

Product design features for ease-of-use and patient safety and comfort

ArrowADVANTAGE⁵ PICCs have increased radiopacity² for visualization under fluoroscopy and x-ray, 5 ml/sec pressure injection indication in the distal lumen and compatibility with the VasoNova VPS stylet. The ArrowADVANTAGE⁵ PICC's unique features include:

• Arrow Blue FlexTip® designed to minimize vessel trauma
• Staggered exit ports to reduce the risk of incompatible medications mixing and forming precipitate³
• GlideThru™ peel-able sheath over dilator to reduce the need for a skin nick
• SecondSite™ adjustable hub to fasten the catheter at insertion site anywhere along the catheter body
• TaperFree™ catheter design to minimize risk of catheter-related thrombosis^4,5.

Catheter-related thrombosis is an important clinical matter to consider. A study in the Journal of Vascular and Interventional Radiology⁴ reported that the risk of thrombosis rises as French size increases. In this study, thrombosis rates increased more than nine fold when comparing 4Fr to 6Fr sized catheter thrombosis outcomes. Tapered catheter bodies can have considerable difference in French size between the tip and proximal end, putting the widest portion of the catheter into the narrowest portion of the vein.

Maximal Barrier Precautions Tray supports adherence to guidelines

The ArrowADVANTAGE⁵ PICC will be packaged with the Arrow^® ErgoPack^™ System, which provides Maximal Barrier Precautions and equips caregivers with 30 systematically organized essential tools to follow guidelines recommended by leading organizations. These include the Centers for Disease Control and Prevention (CDC), Society for Healthcare Epidemiology of America (SHEA) and the Institute for Healthcare Improvement (IHI).

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,600 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at http://www.teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, Arrow, Arrow Blue FlexTip, GlideThru, SecondSite, TaperFree and ErgoPack are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

¹Meets VasoNova VPS Stylet requirements for use.

²Increased radiopacity over currently marketed 4 French and 5 French Arrow Pressure-Injectable PICCs. Data on file. Teleflex Incorporated.

³ Collins JL, Lutz RJ. In Vitro Study of Simultaneous Infusion of Incompatible Drugs in Multilumen Catheters. Heart & Lung. 1991; 20(3):271-7.

⁴ Grove JR, Pevec WC. "Venous Thrombosis Related to Peripherally Inserted Central Catheters." Journal of Vascular and Interventional Radiology. 2000; 11: 837-840.

⁵ Trerotola, S., Stravropoulos, S., Mondeschein, J., Patel, A., Fishman, N., Fuchs, B., Kolansky, D., Kasner, S., Pryor, J., Chittams, J. Triple-Lumen Peripherally Inserted Central Catheter in Patients in the Critical Care Unit: Prospective Evaluation. Radiology. 2010; 256 (1.2).)